Upregulation and Secretion of Kallikrein-related Peptidase 6 (KLK6) in Gastric Cancer

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2012 Mar 1

PMID 22373580

Citations 12

Authors

Jin Ju Kim

Jong-Tae Kim

Hyo Ran Yoon

Min Ah Kang

Joo Heon Kim

Young-Ha Lee

Jae Wha Kim

Seon-Jin Lee

Eun Young Song

Pyung Keun Myung

Hee Gu Lee

Affiliations

Soon will be listed here.

Abstract

KLK6 encoding kallikrein-related peptidase 6, a trypsin-like serine protease, has been shown to be upregulated in several cancers, although the tumorigenic role of KLK6 has not been elucidated. In this study, KLK6 was identified as a highly upregulated gene in gastric cancer; therefore, the possibility that KLK6 might be a suitable candidate tumor marker was examined. RT-PCR and immunohistochemical analysis showed overexpression of KLK6 in gastric cancer tissues compared to nontumor regions. Sera from gastric cancer patients had a 1.7-fold increase in KLK6 (373.1 μg/L, P = 0.048) compared to healthy individuals (214.2 μg/L), although there was no significant difference among patients with various tumor stages. Cellular invasiveness decreased by 45% in cells transfected with KLK6-specific small interfering RNA. Exogenous overexpression of KLK6 led to decreased activity of the E-cadherin promoter. This study shows that KLK6 is significantly upregulated and secreted in gastric cancer tissues and sera, suggesting that KLK6 might be used as a potential biomarker and therapeutic target for gastric cancer.

Citing Articles

Oxazolidinones as versatile scaffolds in medicinal chemistry.

Fernandes G, Scarim C, Kim S, Wu J, Castagnolo D RSC Med Chem. 2023; 14(5):823-847.

PMID: 37252095 PMC: 10211318. DOI: 10.1039/d2md00415a.

KLK6/PAR1 Axis Promotes Tumor Growth and Metastasis by Regulating Cross-Talk between Tumor Cells and Macrophages.

Hwang Y, Cho H, Park E, Lim J, Yoon H, Kim J Cells. 2022; 11(24).

PMID: 36552865 PMC: 9777288. DOI: 10.3390/cells11244101.

Silencing of kallikrein-related peptidase 6 attenuates the proliferation, migration, and invasion of gastric cancer cells through inhibition of epithelial-mesenchymal transition.

Zhou D, He Y, Li H, Huang W Exp Ther Med. 2021; 22(1):770.

PMID: 34055069 PMC: 8145264. DOI: 10.3892/etm.2021.10202.

Identification of Prognostic Biomarkers and Drugs Targeting Them in Colon Adenocarcinoma: A Bioinformatic Analysis.

Dong S, Ding Z, Zhang H, Chen Q Integr Cancer Ther. 2019; 18:1534735419864434.

PMID: 31370719 PMC: 6681251. DOI: 10.1177/1534735419864434.

Biochemical pathways mediated by KLK6 protease in breast cancer.

Pampalakis G, Zingkou E, Sidiropoulos K, Diamandis E, Zoumpourlis V, Yousef G Mol Oncol. 2019; 13(11):2329-2343.

PMID: 30980596 PMC: 6822253. DOI: 10.1002/1878-0261.12493.

References

Luo L, Soosaipillai A, Grass L, Diamandis E . Characterization of human kallikreins 6 and 10 in ascites fluid from ovarian cancer patients. Tumour Biol. 2006; 27(5):227-34. DOI: 10.1159/000094693. View

Anisowicz A, Sotiropoulou G, Stenman G, Mok S, Sager R . A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med. 1996; 2(5):624-36. PMC: 2230195. View

Yousef G, Borgono C, Popalis C, Yacoub G, Polymeris M, Soosaipillai A . In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. Anticancer Res. 2004; 24(1):43-51. View

Diamandis E, Yousef G, Soosaipillai A, Bunting P . Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin Biochem. 2000; 33(7):579-83. DOI: 10.1016/s0009-9120(00)00182-x. View

Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Inoue H, Nagahara H . Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res. 2005; 11(8):2889-93. DOI: 10.1158/1078-0432.CCR-04-2281. View

Santin A, Diamandis E, Bellone S, Soosaipillai A, Cane S, Palmieri M . Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res. 2005; 11(9):3320-5. DOI: 10.1158/1078-0432.CCR-04-2528. View

Diamandis E, Yousef G, Soosaipillai A, Grass L, Porter A, Little S . Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem. 2000; 33(5):369-75. DOI: 10.1016/s0009-9120(00)00145-4. View

Ni X, Zhang W, Huang K, Wang Y, Ng S, Mok S . Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer. 2004; 91(4):725-31. PMC: 2364785. DOI: 10.1038/sj.bjc.6602041. View

Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K . Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002; 16(6):1243-56. DOI: 10.1210/mend.16.6.0874. View

10.

Paliouras M, Borgono C, Diamandis E . Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 2007; 249(1):61-79. DOI: 10.1016/j.canlet.2006.12.018. View

11.

Stenman U . New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease. Clin Chem. 1999; 45(6 Pt 1):753-4. View

12.

Nagahara H, Mimori K, Utsunomiya T, Barnard G, Ohira M, Hirakawa K . Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res. 2005; 11(19 Pt 1):6800-6. DOI: 10.1158/1078-0432.CCR-05-0943. View

13.

Tanimoto H, UNDERWOOD L, Shigemasa K, Parmley T, OBrien T . Increased expression of protease M in ovarian tumors. Tumour Biol. 2000; 22(1):11-8. DOI: 10.1159/000030150. View

14.

Takeichi M . Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol. 1993; 5(5):806-11. DOI: 10.1016/0955-0674(93)90029-p. View

15.

Bayes A, Tsetsenis T, Ventura S, Vendrell J, Aviles F, Sotiropoulou G . Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol Chem. 2004; 385(6):517-24. DOI: 10.1515/BC.2004.061. View

16.

Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, Sotiropoulou G . A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. Cancer Res. 2009; 69(9):3779-87. DOI: 10.1158/0008-5472.CAN-08-1976. View

17.

Palmer H, Sanchez-Carbayo M, Ordonez-Moran P, Larriba M, Cordon-Cardo C, Munoz A . Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res. 2003; 63(22):7799-806. View

18.

Kim J, Song E, Chung K, Kang M, Kim J, Kim S . Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer. Cancer. 2011; 117(12):2608-19. DOI: 10.1002/cncr.25841. View

19.

Ghosh M, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis E . Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol. 2004; 25(4):193-9. DOI: 10.1159/000081102. View

20.

McCormack R, Rittenhouse H, Finlay J, Sokoloff R, Wang T, Wolfert R . Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 1995; 45(5):729-44. DOI: 10.1016/s0090-4295(99)80076-4. View